Statistics from Altmetric.com
The comment provided by Joob and Wiwanitkit contains serious factual errors that need to be urgently corrected to prevent harm to patients.1 Their claim that ‘there is no case of SLE with covid-19’ is false. It is puzzling how they can make such a claim without providing supporting evidence. An initial analysis of patients included in the COVID-19 Global Rheumatology Alliance registry shows that 19 (17%) of 110 patients with rheumatic diseases who have been diagnosed with COVID-19 as of 1 April 2020 were patients with lupus.2 The frequency of patients with lupus who have been diagnosed with COVID-19 was over-represented at ~50% of that reported for rheumatoid arthritis, a disease that is ~4 to 8 times more prevalent than lupus in the adult population in the USA.3 Although selection and reporting bias and differences in comorbidities might contribute to this disproportionately high frequency of COVID-19 in patients with lupus, there is reason to be cautious. Evidence supported by mechanistic data indicates that patients with lupus are inherently more susceptible to viral infections.4 Indeed, we recently suggested that patients with lupus might be particularly more susceptible to severe acute respiratory syndrome (SARS)-CoV-2 infection and to a more complicated course of COVID-19.5
The claim that ‘anti-HIV drug is proven for efficacy against the novel coronavirus’ is also false. The authors here cite another of their own ‘Letter to the Editor’ also making unsupported claims that ‘HIV‐infected patients receiving standard anti‐HIV drug might not have increased risk for COVID‐19’.6
To support their claim that ‘Hydroxychloroquine is also reported for efficacy against covid-19’, the authors cite a review from 2017 before SARS-CoV-2 or COVID-19 was even reported.7 There are multiple ongoing studies and clinical trials under way to examine possible effects of hydroxychloroquine in COVID-19, but the clinical data we have available at this point in time are not convincing.8
Contributors The author fulfilled the following criteria: substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data; drafting the work or revising it critically for important intellectual content; and final approval of the version published.
Funding AHS is funded by the Lupus Research Alliance and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health grant number R01AR070148.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.